Brian Gormley

Plus, Anthropic teams with Novo for AI drug research

Plus, Anthropic teams with Novo for AI drug research

Plus: Billionaires push psychedelic treatments; investor Agora makes first deal

Venture-capital funds are usually 10-year limited partnerships; Luma has stretched that to 15 years instead.

CureDuchenne Ventures aims to raise a $50 million fund to back startups seeking to cure the genetic disease Duchenne muscular dystrophy.

With $50 million in hand, Network Bio plans to offer virtual access to tissue and blood samples from major academic hospitals.

Rare Ventures, which just launched with up to $25 million, will employ ‘venture philanthropy’ to find treatments for an array of uncommon disorders.

Biotech raises $128.7 million to continue its work on genetic medicines to reduce cardiovascular disease.

Reacting to concerns about fraud, Medicare has proposed ending payments to third-party vendors of the services—jolting VCs and startups.

Lingering unease from the recent financing downturn is leading more biotechnology startups to go public by “reverse merging” with a public company.